Breast cancer cells express the chemokine receptor CXCR4 and frequently metastasize to organs with an abundant source of the CXCR4 ligand, stromal cell-derived factor 1 (SDF-1). The chemokine receptor CXCR4 plays an active role in the metastasis of breast cancer. Here, we show that a small interfering RNA (siRNA) against CXCR4 effectively downregulates CXCR4 expression in human MDA-MB-231 breast cancer cells, leading to significant decrease in breast cancer cell invasion and adhesion. It was further found that tumor cells lacking CXCR4 expression proliferated at a much slower rate than control cells in vitro. Surprisingly, tumor cells lacking CXCR4 expression failed to grow in SCID mice in repeated experiments, providing the first direct evidence for an essential role of CXCR4 in breast cancer growth in vivo. This finding suggests an expanded role for the CXCR4 molecule in tumor cell growth in vivo, in addition to its role in breast cancer metastasis. This study implies the CXCR4 molecule as a potential target to control breast tumor growth as well as metastasis. Cancer Gene Therapy (2005) Complete disruption of the CXCR4 chemokine receptor gene is embryologically lethal in mice, 11,12 impeding direct study of CXCR4-mediated tumor progression and metastasis. Current approaches to study CXCR4-mediated tumor metastasis are based on the functional blocking of CXCR4 on tumor cell surfaces with CXCR4 antagonists 13 and CXCR4 neutralizing antibodies. 14 The results of such studies using different cancer cell lines show that inhibition of CXCR4 reduces the frequency of metastasis 13, 14 suggesting that the receptor is essential for tumor-cell dissemination and invasion of tissues.
C hemokines are small proteins that stimulate and attract leukocytes to sites of inflammation.
1 CXCR4, the receptor for SDF-1/CXCL12, plays an important role in lymphocyte trafficking. 2, 3 Breast and other cancer cells express the chemokine receptor CXCR4, and frequently metastasize to organs that are an abundant source of its ligand, SDF-1. 4, 5 Recent reports indicate that CXCR4 is intimately involved in the metastasis of several different types of cancer, including prostate cancer, 6 renal cancer, 7 neuroblastoma, 8 ovarian cancer, 9 breast cancer, 4 and melanoma. 10 Complete disruption of the CXCR4 chemokine receptor gene is embryologically lethal in mice, 11, 12 impeding direct study of CXCR4-mediated tumor progression and metastasis. Current approaches to study CXCR4-mediated tumor metastasis are based on the functional blocking of CXCR4 on tumor cell surfaces with CXCR4 antagonists 13 and CXCR4 neutralizing antibodies. 14 The results of such studies using different cancer cell lines show that inhibition of CXCR4 reduces the frequency of metastasis 13, 14 suggesting that the receptor is essential for tumor-cell dissemination and invasion of tissues.
We chose to use small interfering RNA (siRNA) as a means to constitutively inhibit CXCR4 expression in tumor cells, thus facilitating a more vigorous assessment of the role of CXCR4 in tumor metastasis. Unexpectedly, we found that stable transduction of MDA-MB-231 breast cancer cells with siRNA targeting CXCR4 completely abrogated tumor growth in SCID mice. The results of this study suggested that, in addition to its established role in tumor metastasis, CXCR4 expression contributes importantly to tumor growth in vivo, implicating this chemokine receptor as a potentially valuable therapeutic target to control both breast tumor growth and metastasis.
Materials and methods

Generation of DNA constructs and stably transformed tumor cells
Several 19 nt target sequences were chosen empirically from the full-length human CXCR4 cDNA sequence. All CXCR4 target and CXCR4 mutant sequences were subjected to NCBI Blast query to confirm the lack of homology to other known genes. One of the siRNA expression vectors was constructed as follows: two complementary oligonucleotides 5 0 -GATCCCCTCCTG GCCTTCATCAGTCTTTCAAGAGAAGACTGATGAA GGCCAGGATTTTTGGAAA-3 0 and 3 0 -GGGAGGACC GGAAGTAGTCAGAAAGTTCTCTTCTGACTACTTC CGGTCCTAAAAACCTTTTCGA-5 0 encoding a siRNA against the 19 nt sequence 5 0 -TCCTGGCCTTCATCAG TCT-3 0 of human CXCR4 were annealed, phosphorylated, and ligated into a BglII/HindIII digested pSUPER vector. 15 Sequences of CXCR4 mutant siRNA oligos were 5 0 -GATCCCCTCCT GGTCTTCGTCAGCCTTTC AAGAGAAGGCTGACGAAGACCAGGATTTTTGGA AA-3 0 and 3 0 -GGGAGGACCAGAAGCAGTCGGAAA GTTCTCTTCCGACTGCTTCTGGTCCTAAAAACCT TTTCGA-5 0 . Positive clones were identified by restriction digesting and confirmed by sequencing. MDA-MB-231 human breast cancer cell line (ATCC) was cultured in RPMI (Invitrogen) supplemented with 10% FCS (Invitrogen). MDA-MB-231 cells were cotransfected with the pSuper siRNA construct and pRc/CMV (encoding the geneticin-resistance gene) using a standard electroporation protocol. After 48 hours, cells were transferred to the selection medium, which contained 800 mg/ml of geneticin (Invitrogen) in RPMI with 10% FBS. Several cell colonies were selected and propagated after 10 days of incubation in selective medium.
Flow cytometry
Cells were stained with PE-conjugated anti-human CXCR4 or PE-conjugated mouse IgG2a isotype control (Becton Dickinson, Pharmigen). Assays were performed in triplicate with a FACScan instrument (Becton Dickinson).
Semiquantitative RT-PCR analysis
Total RNA was isolated using TRIzol Reagent (Invitrogen) and reverse transcribed using SuperScript Reverse Transcriptase kit (Invitrogen). Multiplex relative RT-PCR quantification was performed using primers (5 ' -TTC CGCAAGTTCACCTACC-3 ' and 5 0 -CGGGCCGGCCA TGCTTTACG-3 0 ) for the 15S ribosomal protein sequence as previously described. 16 The following gene-specific primer sequences for the human CXCR4 gene: 5 0 -GGTG GTCTATGTTGGCGTCT-3 0 and 5 0 -TGGAGTGTGAC AGCTTGGAG-3 0 , and for the human CXCR2 gene: 5 0 -A AGGACCGTCTACTCATCC-3 0 and 5 0 -ACGAAGACG GGGTACACC-3 0 were used in RT-PCR.
In vitro invasion assay
MDA-MB-231 cell invasion was assayed in 24-well Biocoat Matrigel invasion chambers (8 mm; Becton Dickinson) according to the manufacturer's protocol. Briefly, cells (1 Â 10 4 ) were plated in 0.2 ml of RPMI with 0.25% BSA in the top compartment. The bottom compartment contained 300 ng/ml SDF-1a (Becton Dickinson) in 0.25% BSA/RPMI as a chemoattractant. After 24 hours of incubation, the noninvasive cells were removed with a cotton swab. The cells that migrated through the membrane and adhered to the lower surface of the membrane were fixed and stained with 20% ethanol and 1% crystal violet solution. For quantification, cells were counted under a microscope in five predetermined fields.
Assays were performed in triplicate. The data were reported as the percentage of cells successfully passing through the Matrigel matrix and membrane relative to those migrating through the control membrane, as recommended by the manufacturer's manual.
MTT assay
MTT experiments were carried out using the cell proliferation kit (Roche Diagnostics), according to the manufacturer's manual. Briefly, cells were seeded at a concentration of 2 Â 10 4 cells/cm 2 in 96-well plates in order to obtain approximately 40% confluence. In all the experiments, cells were allowed to grow for 48 hours in medium supplemented with 10% FCS. The cells were incubated for 4 hours with the tetrazolium salts, and the purple formazan crystals were solubilized for 14 hours at 371C and 5% CO 2 . Absorbance was determined at 590 nm with an ELISA reader.
Plating efficiency
Plating efficiency was determined as described 17 by placing 5 Â 10 5 MDA-MB-231 onto 3.5-cm tissue culture dishes. The cells were allowed to adhere for 6 hours at 371C and 5% CO 2 . Cells floating in media were then collected as the nonadherent fraction. Adherent cells were removed by treatment with 0.25% trypsin containing 1 mM EDTA (Invitrogen) and collected. Cells in both populations were counted in five fields with a hemacytometer. The ratio of adherent cells to nonadherent cells was calculated to determine plating efficiency. The assays were performed in triplicate.
Tumor growth in vivo
A total of 5 Â 10 5 stably transduced MDA-MB-231 cells were injected into the mammary fat pads of six B17 SCID female mice in each of groups. Tumor growth was monitored every 3 or 4 days.
Data analysis
Statistical significance was assessed by comparing mean (7SD) values with Student's t-test for independent groups. Pr0.01 was considered statistically significant.
Results and discussion
In order to genetically knockdown CXCR4 expression on the surface of MDA-MB-231 tumor cells, we used a DNA-based siRNA method. 15 Three siRNAs targeting different 19 nt sequences of human CXCR4 separated by a 9-nt spacer were cloned into a pSuper vector for expression as siRNAs from the polymerase-III H1 RNA promoter (data not shown), as described previously. (Fig 1) , showed downregulated expression of surface CXCR4, as determined by flow cytometric analysis. Four out of five selected clones had a downregulated CXCR4 expression. Clone 5-4 showed a complete knockdown of CXCR4 expression, compared with control clone 7-2 that was transduced with an empty pSuper vector (Fig 2a) . The surface levels of CXCR4 in all of the three selected clones transduced with a CXCR4 mutant siRNA were comparable to the level detected on parental MDA-MB-231 cells, indicating the specific downregulation of CXCR4 by CXCR4 siRNA. CXCR4 expression in pSuper transduced clones also did not alter from the levels in intact MDA-MB-231 cells. After passaging these cell lines for 3 months in vitro, the CXCR4 expression levels remained stable, as confirmed by flow cytometry 
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analysis (data not shown). Semiquantitative RT-PCR analysis of clone 5-4 confirmed that the observed knockdown in CXCR4 protein was consistent with the downregulation of CXCR4 mRNA (Fig 2b) . Despite significant modulation of endogenous CXCR4, expression of the related CXCR2 gene remained unchanged in clone 5-4 compared to pSUPER-transduced control cells (clone 7-2), indicating the specificity of the siRNA construct for CXCR4 downregulation (Fig 2b) . We next determined if downregulation of CXCR4 expression by the pSUPER-siRNA-CXCR4 vector could reduce the metastatic potential of the otherwise highly invasive MDA-MB-231 breast cancer cells in response to SDF-1 stimulation. Results of an in vitro invasion assay showed that CXCR4-negative cells (clone 5-4) were completely noninvasive. In contrast, CXCR4-positive cells (clone 7-2) were highly invasive in response to SDF-1 stimulation (Fig 3a) , indicating that downregulation of CXCR4 had impaired the ability of the breast cancer cells to migrate. This result is consistent with previous reports that MDA-MB-231 cells with downregulated CXCR4 expression were unable to migrate toward SDF-1. 19, 20 When examining cell proliferation rates by the MTT assay, we unexpectedly found that the CXCR4-negative cells (clone 5-4) grew significantly slower than the CXCR4-positive cells (clone 7-2) in repeated experiments (Fig 3b) , suggesting that CXCR4 may be involved in the regulation of cell proliferation as well.
To determine how CXCR4 knockdown might influence cell growth and tumor metastasis in vivo, we examined the growth rate and metastatic potential of the transduced MDA-MB-231 cells in SCID mice after their inoculation into mammary fat-pads. We inoculated CXCR4 knockout clones 5-4 and 5-2. CXCR4 expression in 5-4 cells was completely abrogated. None of the mice inoculated with the CXCR4-negative 5-4 cells developed tumors and remained tumor free up to 45 days postinoculation. About 0.5% of cells of clone 5-2 expressed CXCR4 and therefore tumor growth was determined about 45 days after cell inoculation. By contrast, all mice inoculated with pSuper-transduced CXCR4-positive MDA-MB-231 cells (clone 7-2) developed tumors within 3 weeks (Fig 4a) . A significant number of metastases in lungs were observed in the mice inoculated with CXCR4-positive MDA-MB-231 clone 7-2, but no lung metastasis in the mice inoculated with CXCR4-negative clone 5-4 (Fig 4b) . These results were reproducible in repeated experiments. In addition, it was found that the growth rate of a CXCR4-positive MDA-MB-231 clone which was transduced with a siRNA targeting CXCR4 was similar to that of pSuper-transduced CXCR4-positive MDA-MB-231 cells (clone 7-2) in SCID mice (data not shown), implying that the inability of the CXCR4-negative clone 5-4 to grow in SCID mice was not due to potential nonspecific effects of siRNA. Taken together, we conclude that CXCR4 molecules may play a critical role in the growth of the breast cancer in vivo.
To examine whether CXCR4 plays a role in tumor cell adhesion, which may contribute to the establishment of tumors in vivo, we compared the plating efficiency of CXCR4-positive and CXCR4-negative MDA-MB-231 cells. CXCR4-negative cells (clone 5-4) were nine times less adherent than CXCR4-positive control cells (clone 7-2) in the plating efficiency assay (Fig 4c) . Thus, it seems reasonable to postulate that the knockdown of CXCR4 may disrupt cell adhesion in the tumor microenvironment that may be important for tumor establishment and subsequent growth in vivo.
CXCR4 is thought to be primarily involved in breast tumor metastasis. 4, 5, 21 Our study provides the first direct evidence that CXCR4 may play a critical role in breast tumor growth in vivo. This unexpected finding appears significant, because it implies that one might profitably target CXCR4 to combat breast cancer and possibly other cancers by blocking tumor growth as well as metastasis. However, in this study, we only tested the effect of CXCR4 downregulation on in vivo tumor growth in one CXCR4-positive tumor cell line, and, therefore, it is necessary to use additional CXCR4-positive tumor cells to confirm this interesting observation in a future study.
A requirement for CXCR4 in breast cancer growth is suggested by several recent reports. In one study, an anti-CXCR4 neutralizing antibody was found to inhibit brain tumor cell proliferation. 22 Furthermore, in human CXCR4 knockdown abrogates breast tumor growth N Lapteva et al glioblastoma cell lines, SDF-1-dependent proliferation was correlated with phosphorylation and activation of both extracellular signal-regulated kinases 1/2 and Akt, which are involved in cell proliferation. 22 Another study demonstrated that SDF-1 stimulation of cells expressing CXCR4 led to rapid activation of LIMK-1 and extracellular signal-related kinases, which regulate cell proliferation and the cellular motility machinery. 21 It was also reported that neutralizing antibody to SDF-1 decreased the proliferation of bone-homing metastatic prostate cancer cells.
14 Most recently, Zeelenberg et al 25 reported that blocking the surface expression of CXCR4 with an ''intrakine'', developed in our laboratory, 23, 24 greatly reduced the ability of CT26 colon cancer cells to metastasize to the liver and lungs. This effect was not attributed to the inhibition of tumor cell invasion, but rather to the impairment of outgrowth of micrometastases. Further studies are underway to determine the molecular pathways and mechanisms that account for the inhibition of tumor growth in vivo when CXCR4 expression is downregulated by siRNA in different cancer cell lines. Plating efficiency of transduced MDA-MB-231 cells. Cells were allowed to adhere for 6 hours at 37 o C and 5% CO 2 . Adherent and nonadherent cells were collected and counted in five fields. Plating efficiency was determined three times for each clone, and reported as the ratio of nonadherent to adherent cells (mean7SD). Po0.01, compared with pSuper-transduced control clone . Assays were performed in triplicate.
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